

TABLE OF CONTENTS

July 24, 2006

No. 1993

BUSINESS

- 1 Torrent Seeks Alliances with Japanese Companies
- 2 Teijin Pharma to Focus on New Drug Development in the US, Europe
 - 3 Product Launches Expected This Year in Japan
- 5 Astellas to Promote Vesicare as 1st Choice OAB Treatment
- 5 Bushu Aims to Become No. 1 Contract Drug Maker in Japan
- 6 InCROM Increases Number of Beds for Clinical Trials
- 6 *Ryukaikon* Should Settle Old Problems before Tackling New Ones: JPMA
- 7 **BUSINESS NEWS IN BRIEF**
 - Meiji Dairies Licenses TAC-201 to Taiho
 - Takeda Licenses Antibodies for Cancer from Galaxy
 - Daiichi Sankyo Europe Acquires Marketing Rights to Evista in Europe
 - Daiichi Sankyo's European Subsidiary Changes Name
 - Takara Bio to Aggressively Develop Business in the US, China
 - Eisai, Teva End Agreement to Comarket, Codevelop Rasagiline

GENERIC

- 8 Sandoz K.K. Aims for Sharp Increase in Sales by 2010
- 8 Nichi-iko Strengthening Customer Relations, Distribution System
 - New Prescription Form Contributes to Strong 1st Half
- 9 Meiji Seika Aims for ¥10 Bil. in Generic Drug Sales in FY2008
- 9 Kotobuki Pharm. Improved Business by Outsourcing Distribution
- 10 **GENERIC NEWS IN BRIEF**
 - Towa Pharmaceutical Launches 22 New Products
 - Taiyo Pharm.: Sales Up 20.9% in 1st Qtr
 - *Chuikyo* to Survey Pharmacies on Use of Generic Drugs
- 10 **NEW PRODUCTS**
 - Nippon Kayaku: Paclitaxel Injection NK

REGULATORY

- 11 Basic Policies 2006 Call For Enhancement of Drug Industry's Int'l Competitiveness
- 11 *Chuikyo* Discusses Frequency of NHI Drug Price Revisions
 - Drug Cost, Ratio Increased in Last 5-Year Period: Prof. Tsuchida
- 12 Annual NHI Price Revision Would Cause Confusion: Mr Henmi of *Nichibyokyo*
- 12 **REGULATORY NEWS IN BRIEF**
 - ONO-5920/YM529 Applied for Osteoporosis: Ono, Astellas
 - Avastin Filed in the EU as 1st-line Treatment for Advanced Breast Cancer
 - Abolition of ICHQ1F Notified
 - Voluntary Pharmaceutical Excipient GMP to Be Revised Next April: JPEC
 - Gov't to Hurt Healthcare Quality by Reform: Mr Sengoku
 - Number of Deaths after Tamiflu Administration Increased: PFSB
 - Notification Calls For Revision of Precautions for 3 Drugs

- 14 **Survey**
 - R&D Focusing on CV, Anticancer, Neuropsychiatric Drugs: Fuji Keizai
 - Pharmacists Prefer to Get Info. from Study Meetings

MEDICAL DEVICES

- 15 PII Study on Implanted Cardiac Assist Device Initiated
- 15 **NEW PRODUCTS**
 - ARKRAY: AUTION MAX AX4030 Automated Urine Test System
- 15 **MEDICAL DEVICE NEWS IN BRIEF**
 - Daiichi Pure Chemicals, Toshiba to Codevelop *In Vitro* Diagnostics for HPV
 - Olympus Establishes Holding Company in China
- 17 **TOPICS**
 - Sysmex America Receives Premier Pinnacle Award

COMMENTARY

- 16 **Maurer's Healthcare Insight (77)**
 - Hooray for People in Healthcare: P. Reed Maurer

R&D

- 18 Efficacy of Anti-obesity Drug Confirmed in PII: Shionogi
- 18 **R&D NEWS IN BRIEF**
 - Banyu Initiates Clinical Trial of HPV Vaccine GARDASIL
 - TAK-491 Enters into PII in the US, EU: Takeda
 - Baxter Develops Cell-Based Candidate H5N1 Pandemic Vaccine
 - Smoking Cessation Aid Varenicline Shows Good Results in PIII: Pfizer
 - Incidence of AF Reduced by Candesartan: Takeda
 - Nippon Zoki, Argenes to Conduct Joint Clinical Trial of Neurotrophin
 - *Koroshio* Reports Results of 2005 Projects for NIBIO
- 20 Drug Development Beyond Boundaries - Today's Global Cooperative Clinical Trials -: Part II: Behind Pfizer's Decision
- 21 **NEW PRODUCTS**
 - DSP: Amlodin OD Tablets 2.5, 5 mg
 - Pfizer Japan: JZOLOFT Tablets 25, 50 mg
 - Novo Nordisk: Norditropin NordiFlex Injection 15 mg
 - Zeria: Promac D Tablet 75
 - GSK: Flunase Nasal Solution 50 mg 56 Puffs
 - Nippon Organon: Avishot Tablet 75 mg

SELF-MEDICATION

- 22 **SELF-MEDICATION NEWS IN BRIEF**
 - Matsumotokiyoshi to Expand Store-openings, 24-Hour Operation
 - Deregulation May Not Boost Market for OTC Drugs: Mr Kita
- 22 **Seminar**
- 22 Pros and Cons of DTC Marketing Discussed at EBM's Seminar
 - DTC Effective for Promoting Use of Generics
 - DTC Effective in Getting Untreated Patients to Receive Treatment
- 23 Bone Health Should Be Considered with Aromatase Inhibitors